224 related articles for article (PubMed ID: 25221543)
1. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study.
Rasmussen CB; Lindenberg S
Front Endocrinol (Lausanne); 2014; 5():140. PubMed ID: 25221543
[TBL] [Abstract][Full Text] [Related]
2. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Jensterle Sever M; Kocjan T; Pfeifer M; Kravos NA; Janez A
Eur J Endocrinol; 2014 Mar; 170(3):451-9. PubMed ID: 24362411
[TBL] [Abstract][Full Text] [Related]
3. Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with polycystic ovary syndrome: a retrospective study.
Long X; Liu H; Xiong W; Li W; He H; Fu T; Li X; Chen C; Zhang L; Liu Y
Gynecol Endocrinol; 2023 Jun; 39(1):2223648. PubMed ID: 37406658
[TBL] [Abstract][Full Text] [Related]
4. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
Jensterle M; Salamun V; Kocjan T; Vrtacnik Bokal E; Janez A
J Ovarian Res; 2015 Jun; 8():32. PubMed ID: 26032655
[TBL] [Abstract][Full Text] [Related]
5. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese G; de Alteriis G; Muscogiuri G; Barrea L; Verde L; Zumbolo F; Colao A; Savastano S
J Endocrinol Invest; 2023 Sep; 46(9):1761-1774. PubMed ID: 37093453
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
Ferjan S; Janez A; Jensterle M
Metab Syndr Relat Disord; 2017 Dec; 15(10):515-520. PubMed ID: 29064743
[TBL] [Abstract][Full Text] [Related]
8. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Cena H; Chiovato L; Nappi RE
J Clin Endocrinol Metab; 2020 Aug; 105(8):e2695-709. PubMed ID: 32442310
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.
Ge JJ; Wang DJ; Song W; Shen SM; Ge WH
J Endocrinol Invest; 2022 Feb; 45(2):261-273. PubMed ID: 34455568
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.
Bader S; Bhatti R; Mussa B; Abusanana S
Womens Health (Lond); 2024; 20():17455057241234530. PubMed ID: 38444070
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
Tzotzas T; Karras SN; Katsiki N
Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
[TBL] [Abstract][Full Text] [Related]
12. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
Jensterle M; Pirš B; Goričar K; Dolžan V; Janež A
Eur J Clin Pharmacol; 2015 Jul; 71(7):817-24. PubMed ID: 25991051
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis.
Wang FF; Wu Y; Zhu YH; Ding T; Batterham RL; Qu F; Hardiman PJ
Obes Rev; 2018 Oct; 19(10):1424-1445. PubMed ID: 30066361
[TBL] [Abstract][Full Text] [Related]
14. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Jensterle M; Kravos NA; Goričar K; Janez A
BMC Endocr Disord; 2017 Jan; 17(1):5. PubMed ID: 28143456
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide: an injectable option for the management of obesity.
Clements JN; Shealy KM
Ann Pharmacother; 2015 Aug; 49(8):938-44. PubMed ID: 25986009
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
Papaetis GS; Filippou PK; Constantinidou KG; Stylianou CS
Clin Drug Investig; 2020 Aug; 40(8):695-713. PubMed ID: 32583294
[TBL] [Abstract][Full Text] [Related]
17. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.
Nylander M; Frøssing S; Clausen HV; Kistorp C; Faber J; Skouby SO
Reprod Biomed Online; 2017 Jul; 35(1):121-127. PubMed ID: 28479118
[TBL] [Abstract][Full Text] [Related]
18. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
Jensterle M; Kocjan T; Kravos NA; Pfeifer M; Janez A
Endocr Res; 2015; 40(3):133-8. PubMed ID: 25330463
[TBL] [Abstract][Full Text] [Related]
19. The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.
Kahal H; Aburima A; Ungvari T; Rigby AS; Coady AM; Vince RV; Ajjan RA; Kilpatrick ES; Naseem KM; Atkin SL
BMC Endocr Disord; 2015 Apr; 15():14. PubMed ID: 25880805
[TBL] [Abstract][Full Text] [Related]
20. Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial.
Liao M; Li X; Zhang H; Zhou L; Shi L; Li W; Shen R; Peng G; Zhao H; Shao J; Wang X; Sun Z; Zheng H; Long M
Endocrine; 2024 Jan; 83(1):227-241. PubMed ID: 37653215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
